NCT04812509View on ClinicalTrials.gov

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

April 29, 2021

Study Completion Date

January 28, 2022

Conditions
Bone Metastases
Interventions
DRUG

MW032

The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.

DRUG

Xgeva

The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.

Trial Locations (1)

100011

Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT04812509 - Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors | Biotech Hunter | Biotech Hunter